Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0N2JI
|
||||
Former ID |
DIB000799
|
||||
Drug Name |
VAS-203
|
||||
Synonyms |
NOS inhibitor, Vasopharm; Nitric oxide synthase inhibitor, Vasopharm
|
||||
Indication | Brain injury [ICD10:S09.90] | Phase 2 | [548221] | ||
Company |
Vasopharm GmbH
|
||||
Structure |
Download2D MOL |
||||
Canonical SMILES |
c12NC(C(C(O)C)O)CNc1nc(nc2N)N
|
||||
Target and Pathway | |||||
Target(s) | Nitric-oxide synthase, endothelial | Target Info | Inhibitor | [532781] | |
BioCyc Pathway | Citrulline-nitric oxide cycle | ||||
NetPath Pathway | Wnt Signaling Pathway | ||||
Pathway Interaction Database | Plasma membrane estrogen receptor signaling | ||||
Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
Angiopoietin receptor Tie2-mediated signaling | |||||
Thromboxane A2 receptor signaling | |||||
SHP2 signaling | |||||
VEGFR1 specific signals | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
PAR1-mediated thrombin signaling events | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.